Current treatment of mantle cell lymphoma: results of a national survey and consensus meeting.
Witzens-Harig M, Hess G, Atta J, +14 more·Annals of hematology
In most patients, mantle cell lymphoma (MCL) shows an aggressive clinical course with a continuous relapse pattern and a median survival of only 3-5 years. In the current study generation of the European MCL Network, the addition of high-dose Ara-C to R-CHOP (rituximab, cyclophosphamide, doxorubicin, vincristine a…